Product Wiki · Recalls · EU Safety Gate (RAPEX)

COOL GIR — recall SR/03062/26

EU Safety Gate (RAPEX) · Czechia · 2026-10-30 · Serious risk

Compiled from an official source — the facts on this page are reproduced from the issuing authority’s own published notice, which is linked on this page. No AI-generated text appears on this page. How we use AI →
Agency
EU Safety Gate (RAPEX)
Recall identifier
SR/03062/26
Date of alert
2026-10-30
Country / jurisdiction
Czechia
Risk level
Serious risk
Risk type
Chemical
Product category
Cosmetics
Product type
Perfume
Barcode (EAN/GTIN)
6972011065139
🔴 Serious hazard — Reported risk: The product contains allergenic fragrances (Benzyl alcohol, Citronellol, Benzyl salicylate, Coumarin, Hexyl cinnamal, Hydroxycitronellal, D-limonene, Linalool and Alpha-Isomethyl Ionone), which are not mentioned in the list of ingredients. Failure to mention the presence of an allergenic fragrance in the labelling in leave-on products may cause dermatitis/eczema, or more serious skin reactions in already sensitised persons. The product does not comply with the Cosmetic Products Regulation.
What to do

Check whether your product matches this notice (name, batch, dates). If it does, stop using it and follow the instructions in the official notice — refund, return, repair or disposal are set by the issuing authority and the business, and they differ per recall. Official notice from EU Safety Gate (RAPEX) →

Action taken by the authority
Type of economic operator to whom the measure were ordered
Retailer
Category of measure
Destruction of the product
Date of entry into force
15/10/2026
Primary source: https://ec.europa.eu/safety-gate-alerts/screen/webReport/alertDetail/10119431

Verify each fact at the issuing agency before acting. Recall scope, affected lots, and remediation instructions may be updated by the agency after our last sync.

ProductGuru indexes recall and safety-alert records from ~30 public agency registries. We are not lawyers, regulators or product-safety consultants. This page restates what the named agency published; consult the primary source above (or qualified counsel in your jurisdiction) before any commercial, medical or safety decision.